Xeros has published interim results highlighting continued commercial progress, a sharp decrease in overheads and adj. LBITDA falling from -£3.9m to -£2.6m. Cash decreased from £6.5m at the start of the period to £2.6m at the end of August with utilisation below £0.5m/month. We expect further progress in H2 supported by first sales under the Yilmak/KRM contract in Finish and further progress expected in Care, leaving Xeros on track to meet our forecasts for FY2023E. We continue to expect Filtrat ....
